Slowly But Surely

Premium

A few months ago, I headed to Washington, DC, for a forum put on by the Genetics and Public Policy Center, a group affiliated with Johns Hopkins and headed up by Kathy Hudson. The topic was "personal genomes, personal health" — and the consensus of the panel session was that while it's still early days for personalized medicine, it's getting increasingly urgent to figure out how patients will react to it and what some best practices may be.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.